Millennium HealthCare signs exclusive nationwide distribution agreement for an Oral Cancer Biopsy Test

Mar 05, 2013, 09:27 ET from Millennium HealthCare Inc.

GARDEN CITY, N.Y., March 5, 2013 /PRNewswire/ -- Millennium HealthCare Inc. (OTC Pink: MHCC) signed an exclusive nationwide distribution agreement for an Oral Diagnostics Biopsy test.  This non-invasive full thickness biopsy can be used to rule out oral dysplasia or cancer.

Millennium President Chris Amandola commented, "Today's healthcare marketplace continues to move towards preventive care to maintain overall health costs. We are very excited to sign our first exclusive agreement in medical devices focusing on preventive care.  The Oral Cancer Biopsy test uses patented cutting edge technology and with earlier access to patients will provide a meaningful advancement and detection of precancerous cells.  Millennium will begin distributing the product from its New York facility nationwide commencing at the end of the first quarter."

The Oral Cancer Foundation aired a Nationwide Public Service Announcement (PSA) partnering with several known celebrities including Michael Douglas  who emphasized the importance of early oral cancer detection as highlighted in the PSA YouTube link below:


The Oral Cancer Biopsy is an in-office test to help ensure that the harmless-appearing white or red spots in your patient's mouths are not precancerous or cancerous.  According  to the Oral Cancer Foundation, close to 42,000 Americans will be diagnosed with oral or pharyngeal cancer this year. It will cause over 8,000 deaths, killing roughly 1 person per hour, 24 hours per day. Of those 42,000 newly diagnosed individuals, only slightly more than half will be alive in 5 years. (Approximately 57%) This is a number which has not significantly improved in decades. The death rate for oral cancer is higher than that of cancers which we hear about routinely such as cervical cancer, Hodgkin's lymphoma, laryngeal cancer, cancer of the testes, and endocrine system cancers such as thyroid, or skin cancer (malignant melanoma).

The Oral Cancer Biopsy Brush Test is very accurate and has been the subject of well controlled, randomized, clinical trials. In every study in which the same lesion was simultaneously tested with both an Oral Cancer brush and scalpel biopsy, the Oral Brush was shown to be at least as sensitive to a scalpel biopsy in identifying dysplasia or cancer. In addition, the positive and negative predictive values of the Oral Cancer Brush have been repeatedly shown in published studies to be substantially greater than other accepted life-saving tests such as the Pap smear, mammogram, and PSA.

About Millennium HealthCare Inc.

Millennium HealthCare Inc. through its wholly owned operating subsidiaries provide primary care physician practices, physician groups and healthcare facilities of all sizes with cutting edge medical devices focused primarily on preventive care through early detection.  The Company also provides advanced billing & coding services and practice development & management services specializing in cardiology:

Millennium Medical Devices  targets partnerships with medical device companies that provide innovative medical devices that are cost effective, utilize cutting edge technology and are FDA approved.  The devices the company distributes have been selected due to their ability to detect medical issues early with a positive medical outcome.  All of the products the company distributes are reimbursable.

Millennium Coding & Billing offers all aspects of medical billing along with medical diagnosis and procedure coding and training for ICD-10. Our Clinical Documentation Improvement Program Services include concurrent and retrospective CDI Reviews, DRG Validation Services and secure remote and on-site coding. 

Millennium Vascular Management Group offers physician practice development and management services to AMB-SURG facilities & physician practices with a focus on vascular disorders.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995   

Certain written and oral statements made by us may constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Forward-looking statements are identified by such words and phrases as "we expect," "expected to," "estimates," "estimated," "current outlook," "we look forward to," "would equate to," "projects," "projections," "projected to be," "anticipates," "anticipated," "we believe," "could be," and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. Because they are forward-looking, they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.

SOURCE Millennium HealthCare Inc.